Sana Eltayeb, Dan Sunnemark, Anna-Lena Berg, Gunnar Nordvall, Asa Malmberg, Hans Lassmann, Erik Wallström, Tomas Olsson, Anders Ericsson-Dahlstrand
J Neuroimmunol. 2003 Sep; 142(1-2):75-85
DOI: https://doi.org/10.1016/S0165-5728(03)00264-9
Abstract
We have studied the role of the chemokine receptor CCR1 during the effector stage of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in DA rats. In situ hybridization histochemistry revealed local production of the CCR1 ligands CCL3 (MIP-1α) and CCL5 (RANTES), as well as large numbers of CCR1 and CCR5 expressing cells within inflammatory brain lesions. A low-molecular weight CCR1 selective antagonist potently abrogated both clinical and histopathological disease signs during a 5-day treatment period, without signs of peripheral immune compromise. Thus, we demonstrate therapeutic targeting of CCR1-dependent leukocyte recruitment to the central nervous system in a multiple sclerosis (MS)-like rat model.
